HSV-1/2 Antibody (0119): sc-57847

HSV-1/2 Antibody (0119) is a mouse monoclonal IgG antibody that detects the HSV-1/2 protein of HSV 1 and 2 origin by immunofluorescence (IF). Anti-HSV-1/2 antibody (0119) is available as the non-conjugated format, providing researchers with a reliable tool for studying the herpes simplex virus. The herpes simplex virus, comprising two serotypes—HSV-1 and HSV-2—can establish lifelong latent infections within sensory ganglia, which is crucial for understanding pathogenesis and potential therapeutic targets. HSV-1 typically establishes latency in the trigeminal ganglion, while HSV-2 resides in the sacral ganglion at the base of the spine. These viruses can remain dormant in nerve cells, complicating treatment efforts by reactivating periodically and leading to recurrent infections such as cold sores, encephalitis, and genital lesions. The herpes simplex virus structure features a large double-stranded DNA genome encapsulated within an icosahedral nucleocapsid, enveloped by a lipid bilayer. This structural composition aids in viral stability and infectivity while presenting challenges for vaccine development, as viruses can evade the immune system during latent phase. Understanding HSV-1 and HSV-2 dynamics, including latency and reactivation mechanisms, is essential for developing effective treatments and preventive measures against herpes simplex virus infections.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HSV-1/2 Antibody (0119) References:

1. Herpes simplex virus type 2 (HSV-2) infection in women attending an antenatal clinic in the South Pacific island nation of Vanuatu.  |  Haddow, LJ., et al. 2007. Sex Transm Dis. 34: 258-61. PMID: 16940899
2. The microenvironment of vulvar skin in women with symptomatic and asymptomatic herpes simplex virus type 2 (HSV-2) infection.  |  Löwhagen, GB., et al. 2006. J Eur Acad Dermatol Venereol. 20: 1086-9. PMID: 16987263
3. Development and validation of a capillary electrophoresis method for the characterization of herpes simplex virus type 1 (HSV-1) thymidine kinase substrates and inhibitors.  |  Iqbal, J., et al. 2007. J Chromatogr B Analyt Technol Biomed Life Sci. 846: 281-90. PMID: 17023224
4. The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity.  |  Golembewski, EK., et al. 2007. Exp Neurol. 203: 381-93. PMID: 17046754
5. Association between HSV-2 and HIV-1 viral load in semen, cervico-vaginal secretions and genital ulcers of Thai men and women.  |  Chu, K., et al. 2006. Int J STD AIDS. 17: 681-6. PMID: 17059638
6. HSV infection and immunosuppression.  |  Sindhi, R. 2006. Liver Transpl. 12: 1906-7. PMID: 17133569
7. Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas.  |  Robe, PA., et al. 2007. Int J Oncol. 30: 283-90. PMID: 17143539
8. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: role of latency-associated transcripts.  |  Margolis, TP., et al. 2007. J Virol. 81: 1872-8. PMID: 17151134
9. HSV-2- and HIV-1- permissive cell lines co-infected by HSV-2 and HIV-1 co-replicate HSV-2 and HIV-1 without production of HSV-2/HIV-1 pseudotype particles.  |  Legoff, J., et al. 2007. Virol J. 4: 2. PMID: 17207276
10. Negative epidemiological association between HSV-1 and HSV-2 infections.  |  Nasrallah, GK., et al. 2019. Heliyon. 5: e02549. PMID: 31687480
11. A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV.  |  Lince, KC., et al. 2023. Cureus. 15: e35958. PMID: 37041924
12. Detection of HSV-1, HSV-2 and VZV Isolated from Cerebrospinal Fluid Samples of Children Suspected to Encephalitis.  |  Dehghan, G., et al. 2023. Adv Biomed Res. 12: 141. PMID: 37434933

The preferred HSV-1 antibody is HSV-1 Antibody (20.7.1): sc-57863.